These patients are affected more by cachexia and lower albumin levels at the time of diagnosis in comparison to patients from earlier lung cancer stages, and this impacts any potential clinical validation of NPS in NSCLC [39,40,41,42]. The gene discussed is ALB; the disease is Cachexia.